Progress in prion vaccines and immunotherapies

Bibliography

• COLLINGE J: Prion diseases of humans and animals: their causes and molecular basis. Annu. Rev. Neurosci. (2001) 24:519–550.
   PubMed Web of Science ®Google Scholar
• PRUSINER SB: Prions. Proc. Natl Acad. Sci. USA (1998) 95:13363–13383.
   PubMed Web of Science ®Google Scholar
• PRUSINER SB: Novel proteinaceous infectious particles cause scrapie. Science (1982) 216:136–144.
   PubMed Web of Science ®Google Scholar
• BENDHEIM PE, BROWN HR, RUDELLI RD et al.: Nearly ubiquitous tissue distribution of the scrapie agent precursor protein. Neurology (1992) 42:149–156.
   PubMed Web of Science ®Google Scholar
• BOLTON DC, MCKINLEY MP, PRUSINER SB: Identification of a protein that purifies with the scrapie prion. Science (1982) 218:1309–1311.
   PubMed Web of Science ®Google Scholar
• DONNELLY CA, FERGUSON NM, GHANI AC, ANDERSON RM: Implications of BSE infection screening data for the scale of the British BSE epidemic and current European infection levels. Proc. R. Soc. Lond. B. Biol. Sci. (2002) 269:2179–2190.
   PubMed Web of Science ®Google Scholar
• WILESMITH JW, WELLS GA, CRAN WELL MP, RYAN JB: Bovine spongiform encephalopathy: epidemiological studies. Vet. Rec. (1988) 123:638–644.
   PubMed Web of Science ®Google Scholar
• WILL RG, IRONSIDE JW, ZEIDLER Met al.: A new variant of Creutzfeldt-Jakob disease in the UK. Lancet (1996) 347:921–925.
   Google Scholar
• BRUCE ME, WILL RG, IRONSIDE JW et al.: Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature (1997) 389:498–501.
   PubMed Web of Science ®Google Scholar
• HILL AF, DESBRUSLAIS M, JOINERS et al.: The same prion strain causes vCJD and BSE. Nature (1997) 389:48-50, 526.
   Google Scholar
• LLEWELYN CA, HEWITT PE, KNIGHT RS et al: Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion Lancet (2004) 363:417–421.
   Google Scholar
• PEDEN AH, HEAD MW, RITCHIE DL et al: Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient Lancet (2004) 364:527–529.
   Google Scholar
• AUCOUTURIER P, CARP RI, CARNAUD C, WISNIEWSKI T: Prion diseases and the immune system. Clin. Immunol (2000) 96:79–85.
   PubMed Web of Science ®Google Scholar
• PORTER DD, PORTER HG, COX NA: Failure to demonstrate a humoral immune response to scrapie infection in mice. Immunol (1973) 111:1407–1410.
   Web of Science ®Google Scholar
• KINGSBURY DT, SMELTZER DA, GIBBS CJ, GAJDUSEK DC: Evidence for normal cell-mediated immunity in scrapie-infected mice. Infect. Immun. (1981) 32:1176–1180.
   PubMed Web of Science ®Google Scholar
• PRUSINER SB, GROTH D, SERBAN A, STAHL N, GABIZON R: Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc. Nail Acad. Sci. USA (1993) 90:10608–10612.
   PubMed Web of Science ®Google Scholar
• WEISSMANN C, BUELER H, FISCHER M et al.: PrP-deficient mice are resistant to scrapie. Ann. NY Acad. Sci. (1994) 724:235–240.
   PubMed Web of Science ®Google Scholar
• BUELER H, AGUZZI A, SAILER A et al.:Mice devoid of PrP are resistant to scrapie. Cell (1993) 73:1339–1347.
   PubMed Web of Science ®Google Scholar
• ARBEL M, LAVIE V SOLOMON B: Generation of antibodies against prion protein in wild-type mice via helix peptide immunization. J. NeuroimmunoL (2003) 144:38–45.
   PubMed Web of Science ®Google Scholar
• BAINBRIDGE J, JONES N, WALKER B: Multiple antigenic peptides facilitate generation of anti-prion antibodies. Clin. Exp. ImmunoL (2004) 137:298–304.
   PubMed Web of Science ®Google Scholar
• KOLLER MF, GRAU T, CHRISTEN P: Induction of antibodies against murine full-length prion protein in wild-type mice. J. NeuroimmunoL 2002 132:113–116.
   PubMed Web of Science ®Google Scholar
• ROSSET MB, BALLERINI C, GREGOIRE S, METHAROM P, CARNAUD C, AUCOUTURIER P: Breaking immune tolerance to the prion protein using prion protein peptides plus oligodeoxynucleotides-CpG in mice. J. Immunol. (2004) 172:5168–5174.
   PubMed Web of Science ®Google Scholar
• GREGOIRE S, LOGRE C, METHAROM P et al.: Identification of two immunogenic domains of the prion protein - PrP - which activate class II-restricted T cells and elicit antibody responses against the native molecule. J. Leukoc. Biol. (2004) 76:125–134.
   PubMed Web of Science ®Google Scholar
• EKLUND CM, KENNEDY RC, HADLOW WJ: Pathogenesis of scrapie virus infection in the mouse. J. Infect. Dis. (1967) 117:15–22.
   PubMed Web of Science ®Google Scholar
• FRASER H, DICKINSON AG: Pathogenesis of scrapie in the mouse: the role of the spleen. Nature (1970) 226:462–463.
   PubMed Web of Science ®Google Scholar
• FRASER H, DICKINSON AG: Studies ofthe lymphoreticular system in the pathogenesis of scrapie: The role of the spleen and thymus. J. Comp. PathoL (1978) 88:563–573.
   PubMed Web of Science ®Google Scholar
• KIMBERLIN RH, WALKER CA: Pathogenesis of mouse scrapie: Dynamics of agent replication in spleen, spinal cord, and brain after injection by different routes. J. Comp. Pathol. (1979) 89:551–562.
   PubMed Web of Science ®Google Scholar
• VAN KEULEN LJ, SCHREUDER BE, MELOEN RH, MOOIJ-HARKES G, VROMANS ME, LANGEVELD JP: Immunohistochemical detection of prion protein in lymphoid tissues of sheep with natural scrapie. J. Clin. MicrobioL (1996) 34:1228–1231.
   PubMed Web of Science ®Google Scholar
• MCBRIDE PA, EIKELENBOOM P, KRAAL G, FRASER H, BRUCE ME: PrP protein is associated with follicular dendritic cells of spleens and lymph nodes in uninfected and scrapie-infected mice. PathoL (1992) 168:413–418.
   Web of Science ®Google Scholar
• BROWN KL, RITCHIE DL, MCBRIDE PA, BRUCE ME: Detection of PrP in extraneural tissues. Microsc. Res. Tech. (2000) 50:40–45.
   PubMed Web of Science ®Google Scholar
• HILL AF, ZEIDLER M, IRONSIDE JW,COLLINGE J: Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet (1997) 349:99–100.
   PubMed Web of Science ®Google Scholar
• HILTON DA, FATHERS E, EDWARDS P, IRONSIDE JW, ZAJICEK J: Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease. Lancet (1998) 352:703–704.
   PubMed Web of Science ®Google Scholar
• OUTRAM GW, DICKINSON AG, FRASER H: Developmental maturation of susceptibility to scrapie in mice. Nature (1973) 241:536–537.
   Google Scholar
• OUTRAM GW, DICKINSON AG, FRASER H: Reduced susceptibility to scrapie in mice after steroid administration. Nature (1974) 249:855–856.
   PubMed Web of Science ®Google Scholar
• DICKINSON AG, FRASER H, MCCONNELL I, OUTRAM GW: Mitogenic stimulation of the host enhances susceptibility to scrapie. Nature (1978) 272:54–55.
   PubMed Web of Science ®Google Scholar
• FRASER H, FARQUHAR C: Ionising radiation has no influence on scrapie incubation period in mice. Vet. Microbiol. (1987) 13:211–223.
   PubMed Web of Science ®Google Scholar
• SETHI S, LIPFORD G, WAGNER H et al.: Postexposure prophylaxis against prion disease with a stimulator of innate immunity. Lancet (2002) 360:229–230.
   PubMed Web of Science ®Google Scholar
• HEIKENWALDER M, POLYMENIDOU M, JUNT T et al.: Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. (1994) 10:187–192.
   Web of Science ®Google Scholar
• RAEBER AJ, SAILER A, HEGYI I et al.: Ectopic expression of prion protein (PrP) in T lymphocytes or hepatocytes of PrP knockout mice is insufficient to sustain prion replication. Proc. NatL Acad. Sci. USA (1999) 96:3987–3992.
   PubMed Web of Science ®Google Scholar
• O'ROURKE KI, HUFF TP, LEATHERS CW, ROBINSON MM, GORHAM JR: SCID mouse spleen does not support scrapie agent replication. J. Gen. ViroL (1994) 75:1511–1514.
   PubMed Web of Science ®Google Scholar
• LASMEZAS CI, CESBRON J-Y, DESLYS J-P et al.: Immune system-dependent and-independent replication of the scrapie agent. J. Wrol. (1996) 70:1292–1295.
   Google Scholar
• BROWN KL, STEWART K, BRUCE ME, FRASER H: Severely combined immunodeficient (SCID) mice resist infection with bovine spongiform encephalopathy. J. Gen. ViroL (1997) 78:2707–2710.
   PubMed Web of Science ®Google Scholar
• KLEIN MA, FRIGG R, FLECHSIG E et al.: A crucial role for B cells in neuroinvasive scrapie. Nature (1997) 390:687–690.
   PubMed Web of Science ®Google Scholar
• BROWN KL, STEWART K, RITCHIE DL et al.: Scrapie replication in lymphoid tissues depends on prion protein-expressing follicular dendritic cells. Nat. Med. (1999) 5:1308–1312.
   PubMed Web of Science ®Google Scholar
• RAEBER AJ, KLEIN MA, FRIGG R, FLECHSIG E, AGUZZI A. -WEISSMANN C: PrP-dependent association of prions with splenic but not circulating lymphocytes of scrapie-infected mice. EMBO J. (1999) 18:2702–2706.
   Google Scholar
• KITAMOTO T, MURAMOTO T, MOHRI S, DOH-URA K, TATEISHI J: Abnormal isoform of prion protein accumulates in follicular dendritic cells in mice with Creutzfeldt-Jakob disease. ViroL (1991) 65:6292–6295.
   Web of Science ®Google Scholar
• MONTRASIO F, FRIGG R, GLATZEL M et al.: Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. Science (2000) 288:257–259.
   Web of Science ®Google Scholar
• MABBOTT NA, MACKAY F, MINNS F, BRUCE ME: Temporary inactivation of follicular dendritic cells delays neuroinvasion of scrapie. Nat. Med. (2000) 6:719–720.
   PubMed Web of Science ®Google Scholar
• MABBOTT NA, YOUNG J, MCCONNELL I, BRUCE ME: Follicular dendritic cell dedifferentiation by treatment with an inhibitor of the lymphotoxin pathway dramatically reduces scrapie susceptibility. J. Virol. (2003) 77:6845–6854.
   PubMed Web of Science ®Google Scholar
• MABBOTT NA, MCGOVERN G, JEFFREY M, BRUCE ME: Temporary blockade of the tumor necrosis factor receptor signaling pathway impedes the spread of scrapie to the brain. J. ViroL (2002) 76:5131–5139.
   PubMed Web of Science ®Google Scholar
• MABBOTT NA, WILLIAMS A, FARQUHAR CF, PASPARAKIS M, KOLLIAS G, BRUCE ME: Tumor necrosis factor alpha-deficient, but not interleukin-6-deficient, mice resist peripheral infection with scrapie. J. ViroL (2000) 74:3338–3344.
   PubMed Web of Science ®Google Scholar
• MABBOTT NA, BRUCE ME, BOTTO M, WALPORT MJ, PEPYS MB: Temporary depletion of complement component C3 or genetic deficiency of Clq significantly delays onset of scrapie. Nat. Med. (2001) 7:485–487.
   PubMed Web of Science ®Google Scholar
• KLEIN MA, KAESER PS, SCHWARZ P et al.: Complement facilitates early prion pathogenesis. Nat. Med. (2001) 7:488–492.
   PubMed Web of Science ®Google Scholar
• SCHENK D, BARBOUR R, DUNN W et al.: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 400:173–177.
   PubMed Web of Science ®Google Scholar
• JANUS C, PEARSON J, MCLAURIN J et al.: A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2000) 408:979–982.
   PubMed Web of Science ®Google Scholar
• RACE RE, CAUGHEY B, GRAHAM K, ERNST D, CHESEBRO B: Analyses of frequency of infection, specific infectivity, and prion protein biosynthesis in scrapie-infected neuroblastoma cell clones. J. ViroL (1988) 62:2845–2849.
   PubMed Web of Science ®Google Scholar
• BUTLER DA, SCOTT MR, BOCKMAN JM et al.: Scrapie-infected murine neuroblastoma cells produce protease-resistant prion proteins. J. ViroL (1988) 62:1558–1564.
   PubMed Web of Science ®Google Scholar
• NISHIDA N, HARRIS DA, VILETTE D et al.: Successful transmission of three mouse-adapted scrapie strains to murine neuroblastoma cell lines overexpressing wild-type mouse prion protein. J. ViroL (2000) 74:320–325.
   PubMed Web of Science ®Google Scholar
• HARRIS DA: Cell biological studies of theprion protein. Cuff. Issues MoL Biol. (1999) 1:65–75.
   PubMedGoogle Scholar
• LEHMANN S, HARRIS DA: Mutant and infectious prion proteins display common biochemical properties in cultured cells. J. Biol. Chem. (1996) 271:1633–1637.
   PubMed Web of Science ®Google Scholar
• CHIESA R, HARRIS DA: Nerve growthfactor-induced differentiation does not alter the biochemical properties of a mutant prion protein expressed in PC12 cells. Neurochem. (2000) 75:72–80.
   PubMed Web of Science ®Google Scholar
• SCHATZL HM, LASZLO L, HOLTZMAN DM et al.: A hypothalamicneuronal cell line persistently infected with scrapie prions exhibits apoptosis. j ViroL (1997) 71:8821–8831.
   PubMed Web of Science ®Google Scholar
• CAUGHEY B, RACE RE, ERNST D, BUCHMEIER MJ, CHESEBRO B: Prion protein biosynthesis in scrapie-infected and uninfected neuroblastoma cells. J. ViroL (1989) 63:175–181.
   PubMed Web of Science ®Google Scholar
• RACE RE, CAUGHEY B, GRAHAM K, ERNST D, CHESEBRO B: Analyses of frequency of infection, specific infectivity, and prion protein biosynthesis in scrapie-infected neuroblastoma cell clones. J. ViroL (1988) 62:2845–2849.
   PubMed Web of Science ®Google Scholar
• CAUGHEY B, RAYMOND GJ, ERNST D, RACE RE: N-terminal truncation of the scrapie-associated form of PrP by lysosomal protease(s): implications regarding the site of conversion of PrP to the protease-resistant state. J. ViroL (1991) 65:597–603.
   Google Scholar
• ENARI M, FLECHSIG E, WEISSMANN C: Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc. NatL Acad. Sci. USA (2001) 98:9295–9299.
   PubMed Web of Science ®Google Scholar
• PERETZ D, WILLIAMSON RA, KANEKO K et al.: Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature (2001) 412:739–743.
   PubMed Web of Science ®Google Scholar
• BOSQUE PJ, PRUSINER SB: Cultured cell sublines highly susceptible to prion infection. J. ViroL (2000) 74:4377–4386.
   PubMed Web of Science ®Google Scholar
• CAUGHEY B, NEARY K, BULLER R et al.: Normal and scrapie-associated forms of prion protein differ in their sensitivities to phospholipase and proteases in intact neuroblastoma cell. J. ViroL (1990) 64:1093–1101.
   PubMed Web of Science ®Google Scholar
• GILCH S, WOPFNER F, RENNER-MULLER I et al.: Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells. J. Biol. Chem. (2003) 278:18524–18531.
   PubMed Web of Science ®Google Scholar
• CAUGHEY B, RAYMOND GJ: The scrapie-associated form of PrP is made from a cell surface precursor that is both protease-and phospholipase-sensitive. J. ViroL (1991) 266:18217–18223.
   Google Scholar
• GILCH S, WINKLHOFER KF, GROSCHUP MH et al.: Intracellular re-routing of prion protein prevents propagation of PrPsc and delays onset of prion disease. EMBO J. (2001) 20:3857–3966.
   Web of Science ®Google Scholar
• KANEKO K, ZULIANELLO L, SCOTT M et al.: Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc. NatL Acad. Sci. USA (1997) 94:10069–10074.
   PubMed Web of Science ®Google Scholar
• HORIUCHI M, BARON GS, XIONG LW, CAUGHEY B: Inhibition of interactions and interconversions of prion protein isoforms by peptide fragments from the C-terminal folded domain./ Biol. Chem. (2001) 276:15489–15497.
   PubMed Web of Science ®Google Scholar
• BERINGUE V, VILETTE D, MALLINSON G et al.: PrPsc binding antibodies are potent inhibitors of prion replication in cell lines. J. Biol. Chem. (2004) 279:39671–39676.
   PubMed Web of Science ®Google Scholar
• PERRIER V SOLASSOL J, CROZET C et al.: Anti-PrP antibodies block PrPsc replication in prion-infected cell cultures by accelerating PrPc degradation. Neurochem. (2004) 89:454–463.
   PubMed Web of Science ®Google Scholar
• SOUAN L, MARGALIT R, BRENNER O, COHEN IR, MOR F: Self prion protein peptides are immunogenic in Lewis rats. Autoimmun. (2001) 17:303–310.
   Web of Science ®Google Scholar
• SOUAN L, TAL Y, FELLING Y, COHEN IR, TARABOULOS A, MOR F: Modulation of proteinase-K resistant prion protein by prion peptide immunization. Eur. J. ImmunoL (2001) 31:2338–2346.
   PubMed Web of Science ®Google Scholar
• HEPPNER FL, MUSAHL C, ARRIGHI I et al.: Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science (2001) 294:178–182.
   PubMed Web of Science ®Google Scholar
• SCHWARZ A. KRATKE O, BURWINKEL Met al.: Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neurosci. Lett. (2003) 350:187–189.
   Google Scholar
• SIGURDSSON EM, BROWN DR, DANIELS M et al.: Immunization delays the onset of prion disease in mice. Am. J. PathoL (2002) 161:13–17.
   PubMed Web of Science ®Google Scholar
• SIGURDSSON EM, SY M, LI R et al.: Anti-prion antibodies for prophylaxis following prion exposure in mice. Neurosci. Lett. (2003) 336:185–187.
   PubMed Web of Science ®Google Scholar
• WHITE AR, ENEVER P, TAYEBI Met al.: Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature (2003) 422:80–83.
   Google Scholar
• TAL Y, SOUAN L, COHEN-SOLAL M et al.: Complete Freund's adjuvant immunization prolongs survival in experimental prion disease in mice. J. Neurosci. Res. (2003) 71:286–290.
   PubMed Web of Science ®Google Scholar
• POLYMENIDOU M, HEPPNER F, PELLICIOLI EC et al.: Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. Proc. Natl. Acad. Sci. USA (2004) 101\(Suppl. 2):14670–14676.
   Google Scholar
• BANSAL-PAKALA P, JEMBER AG, CROFT M: Signaling through 0X40 (CD134) breaks peripheral T-cell tolerance. Nat. Med. (2001) 7:907–912.
   PubMed Web of Science ®Google Scholar
• MALUCCI G, DICKINSON A, LINEHAN M et al.: Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science (2003) 302:871–874.
   PubMed Web of Science ®Google Scholar
• TELLING GC, SCOTT M, MASTRIANNI J et al.: Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell (1995) 83:79–90.
   PubMed Web of Science ®Google Scholar
• SOLFOROSI L, CRIADO JR, MCGAVERN DB et al.: Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science (2004) 303:1514–1516.
   PubMed Web of Science ®Google Scholar
• KORTH C, STIERLI B, STREIT P et al.:Prion (PrPSc)-specific epitope defined by a monoclonal antibody. Nature (1997) 390:74–77.
   PubMed Web of Science ®Google Scholar
• FISCHER MB, ROECKL C, PARIZEK P, SCHWARZ HP, AGUZZI A: Binding of disease-associated prion protein to plasminogen. Nature (2000) 408:479–483.
   PubMed Web of Science ®Google Scholar
• MORONCINI G, KANU N, SOLFOROSI L: Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc. Proc. NatL Acad. Sci. USA (2004) 101:10404–10409.
   PubMed Web of Science ®Google Scholar
• PARAMITHIOTIS E, PINARD M, LAWTON T et al.: A prion protein epitope selective for the pathologically misfolded conformation. Nat. Med. (2003) 9:893–899.
   PubMed Web of Science ®Google Scholar
• ZOU WQ, CASHMAN NR: Acidic pH and detergents enhance in vitro conversion of human brain PrPC to a PrPSc-like form. Biol. Chem. (2002) 277:43942–43947.
   Web of Science ®Google Scholar
• LEHTO MT, ASHMAN DA, CASHMAN NR: Treatment of ScN2a cells with prion-specific YYR antibodies Proceedings of the First International Conference of the Network of Excellence: Neuroprion. (24 — 28 May 2004) Paris, France.
   Google Scholar
• MCLAURIN J, CECAL R, KIERSTEAD ME et al.: Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4–10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. (2002) 8:1263-1269. Website Dm.
   Google Scholar
• www.cjd.ed.ac.ukhwelfth/rep2003.htm Creutzfeldt—Jakob Disease Surveillance in the UK, Twelfth Annual Report 2003.
   Google Scholar